JP6502939B2 - 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 - Google Patents

骨粗鬆症の処置及び予防のためのガストリン拮抗薬 Download PDF

Info

Publication number: JP6502939B2
Authority: JP; Japan
Prior art keywords: gastrin; bone; hypergastrinemia; cells; ovariectomy
Prior art date: 2013-11-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2016533607A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016538295A (ja

JP2016538295A5 (2

Inventor

マークモドリンアービン

キッドマーク

Original Assignee

シーエルバイオサイエンシズリミティドライアビリティカンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-22

Filing date

2014-11-21

Publication date

2019-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6502939(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-21 Application filed by シーエルバイオサイエンシズリミティドライアビリティカンパニー, シーエルバイオサイエンシズリミティドライアビリティカンパニー filed Critical シーエルバイオサイエンシズリミティドライアビリティカンパニー

2016-12-08 Publication of JP2016538295A publication Critical patent/JP2016538295A/ja

2017-12-28 Publication of JP2016538295A5 publication Critical patent/JP2016538295A5/ja

2019-04-17 Application granted granted Critical

2019-04-17 Publication of JP6502939B2 publication Critical patent/JP6502939B2/ja

Status Active legal-status Critical Current

2034-11-21 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2016533607A 2013-11-22 2014-11-21 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 Active JP6502939B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361907980P	2013-11-22	2013-11-22
US61/907,980		2013-11-22
PCT/US2014/066832 WO2015077572A1 (en)	2013-11-22	2014-11-21	Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (3)

Publication Number	Publication Date
JP2016538295A JP2016538295A (ja)	2016-12-08
JP2016538295A5 JP2016538295A5 (2)	2017-12-28
JP6502939B2 true JP6502939B2 (ja)	2019-04-17

Family

ID=52118000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016533607A Active JP6502939B2 (ja)	2013-11-22	2014-11-21	骨粗鬆症の処置及び予防のためのガストリン拮抗薬

Country Status (14)

Country	Link
US (1)	US10709714B2 (2)
EP (1)	EP3071206B1 (2)
JP (1)	JP6502939B2 (2)
KR (1)	KR102254957B1 (2)
CN (1)	CN106163527A (2)
AU (1)	AU2014352875B2 (2)
BR (1)	BR112016011727A2 (2)
CA (1)	CA2929858C (2)
DK (1)	DK3071206T3 (2)
ES (1)	ES2870538T3 (2)
MX (1)	MX2016006657A (2)
PL (1)	PL3071206T3 (2)
RU (1)	RU2693484C1 (2)
WO (1)	WO2015077572A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10881667B2 (en)	2018-10-30	2021-01-05	City University Of Hong Kong	Method and composition for treating epilepsy
US11285161B2 (en)	2019-04-26	2022-03-29	City University Of Hong Kong	Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) *	2019-11-19	2020-03-31	宁波大学	一种丙谷二肽的新用途
CN115770266B (zh) *	2023-01-30	2023-05-09	云南中医药大学	一种用于治疗绝经后骨质疏松的药物组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989005812A1 (fr) *	1987-12-22	1989-06-29	Yoshitomi Pharmaceutical Industries, Ltd.	Composes de thienodiazepine et leur utilisation en medecine
JPH0374328A (ja)	1989-08-04	1991-03-28	Warner Lambert Co	薬学的活性を有する中枢コレシストキニン拮抗剤
US5399565A (en)	1990-07-17	1995-03-21	Eli Lilly And Company	Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
FI932928A0 (fi)	1990-12-25	1993-06-24	Yamanouchi Pharma Co Ltd	Nya bensodiazepinderivat
CA2110986A1 (en)	1991-07-12	1993-01-21	Geoffrey Neil Woodruff	Cholecystokinin antagonists useful in the treatment of panic attacks
EP0638560A4 (en)	1991-10-11	1995-03-29	Yoshitomi Pharmaceutical	MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1993012817A1 (en) *	1991-12-20	1993-07-08	Warner-Lambert Company	Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en)	1992-02-27	1997-11-20	Yamanouchi Pharma Co Ltd	Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
MY128102A (en)	1993-02-17	2007-01-31	Chugai Pharmaceutical Co Ltd	Indolin-2-one-derivatives
GB2282595A (en)	1993-08-25	1995-04-12	Yamanouchi Pharma Co Ltd	Benzodiazepine derivatives
IT1261255B (it)	1993-09-09	1996-05-09	Rotta Research Lab	Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
US5750353A (en)	1995-12-11	1998-05-12	New England Medical Center Hospitals, Inc.	Assay for non-peptide agonists to peptide hormone receptors
IL124808A0 (en)	1995-12-11	1999-01-26	New England Medical Center Inc	Assay for and uses of peptide hormone receptor ligands
US5922883A (en)	1996-04-03	1999-07-13	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US20040001842A1 (en)	1997-05-12	2004-01-01	Dov Michaeli	Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
ES2227833T3 (es)	1997-05-12	2005-04-01	Aphton Corporation	Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
KR100699574B1 (ko)	1998-05-15	2007-03-23	리셉터 바이오로직스 인크	종양 치료를 위한 조합 치료
CA2333770A1 (en)	1998-06-04	1999-12-09	Abbott Laboratories	Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
WO2000044722A1 (en)	1999-01-29	2000-08-03	Chugai Seiyaku Kabushiki Kaisha	Chondrongenesis promotors and indolin-2-one derivatives
WO2000075145A1 (en)	1999-06-03	2000-12-14	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en)	1999-08-27	2003-10-09	Goldstein Steven Wayne	Urea derivatives useful as anticancer agents
US6844367B1 (en)	1999-09-17	2005-01-18	Millennium Pharmaceuticals, Inc.	Benzamides and related inhibitors of factor Xa
DE60026348T2 (de)	1999-11-05	2006-10-19	Societe De Conseils De Recherches Et D`Applications Scientifiques (S.C.R.A.S.)	Heterocyclische verbindungen und ihre verwendung als medikamente
AU3003701A (en)	1999-11-19	2001-05-30	Axxima Pharmaceuticals Ag	Inhibitors of helicobacter pylori induced gastrointestinal diseases
WO2001077685A2 (en)	2000-04-10	2001-10-18	The General Hospital Corporation	Diagnosis and treatment of gastrointestinal disease
WO2002000651A2 (en)	2000-06-27	2002-01-03	Bristol-Myers Squibb Pharma Company	Factor xa inhibitors
JP2005508838A (ja)	2001-03-23	2005-04-07	アフトンコーポレーション	膵癌の組合せ治療
US20040138285A1 (en)	2001-04-27	2004-07-15	Makoto Okazaki	Chondrogenesis promoters
US20090191232A1 (en)	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
WO2002092096A1 (en)	2001-05-11	2002-11-21	Yamanouchi Pharmaceutical Co., Ltd.	Antitumor agents
AUPR738301A0 (en)	2001-08-30	2001-09-20	Starpharma Limited	Chemotherapeutic agents
BR0213317A (pt)	2001-11-13	2004-10-13	Black James Foundation	Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
US20040127492A1 (en)	2002-02-19	2004-07-01	Pharmacia Corporation	Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
DE10207037A1 (de)	2002-02-20	2003-08-28	Bayer Cropscience Gmbh	2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en)	2002-07-03	2007-07-25	Janssen Pharmaceutica Nv	Cck-1 receptor modulators
US20030049698A1 (en)	2002-10-08	2003-03-13	Wang Timothy C.	Diagnosis and treatment of gastrointestinal disease
KR20050119666A (ko)	2003-03-28	2005-12-21	얀센 파마슈티카 엔.브이.	벤조[1,2,5]티아디아졸 화합물
WO2004101533A1 (en)	2003-05-12	2004-11-25	Janssen Pharmaceutica, N.V.	1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
GB0310865D0 (en)	2003-05-12	2003-06-18	Black James Foundation	Gastrin and cholecystokinin receptor ligands
WO2005007107A2 (en)	2003-07-11	2005-01-27	University Of Massachusetts	Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
SI1651621T1 (sl)	2003-08-08	2008-12-31	Janssen Pharmaceutica Nv	2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
US20070293482A1 (en)	2004-03-19	2007-12-20	Novartis Pharmaceuticals Corporation	Process for Preparing Benzodiazepines
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en)	2004-08-04	2011-05-24	Janssen Pharmaceutica Nv	Preparation of quinoxaline compounds
CA2581426A1 (en)	2004-09-24	2006-04-06	Janssen Pharmaceutica, N.V.	Sulfonamide compounds
WO2006044352A2 (en)	2004-10-12	2006-04-27	Janssen Pharmaceutica N.V.	Canine cholecystokinin 1 receptor materials and their use
AU2005302669A1 (en)	2004-10-27	2006-05-11	Neurogen Corporation	Diaryl ureas as CB1 antagonists
CA2579227A1 (en)	2004-11-04	2006-05-18	Neurogen Corporation	Arylalkyl ureas as cb1 antagonists
GB0425196D0 (en)	2004-11-15	2004-12-15	Black James Foundation	Gastrin and cholecystokinin receptor ligands
US20090291977A1 (en)	2004-12-17	2009-11-26	Madoka Jinno	Chromane Derivatives Useful As Acid Pump Antagonists
DE602006013094D1 (de)	2005-01-19	2010-05-06	Zeria Pharm Co Ltd	Krebsmittel
AR053713A1 (es)	2005-04-20	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006255047B2 (en)	2005-06-06	2011-09-15	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating sleep disorders
DE602006009105D1 (de)	2005-06-14	2009-10-22	Raqualia Pharma Inc	Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
ES2324354T3 (es)	2005-07-29	2009-08-05	Rottapharm S.P.A.	Combinacion terapeutica de itriglumida e inhibidores de la bomba de protones en el tratamiento de trastornos gastrointestinales y relacionados.
WO2007026218A2 (en)	2005-09-01	2007-03-08	Pfizer Japan Inc.	Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en)	2005-09-15	2007-03-22	Pfizer Japan Inc.	Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en)	2005-12-19	2007-06-28	Pfizer Japan Inc.	Benzimidazole-5-carboxamide derivatives
DE602006014996D1 (de)	2005-12-19	2010-07-29	Raqualia Pharma Inc	Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer
JP2009530262A (ja)	2006-03-17	2009-08-27	ラクオリア創薬株式会社	クロマン誘導体
JP2009533362A (ja)	2006-04-12	2009-09-17	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のｎ−オキシド
FR2901473B1 (fr)	2006-05-24	2010-08-13	Oreal	Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
FR2901472B1 (fr)	2006-05-24	2010-08-13	Oreal	Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
ATE512969T1 (de)	2006-09-21	2011-07-15	Raqualia Pharma Inc	Benzimidazolderivate als selektive säurepumpenhemmer
WO2008046082A2 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en)	2006-11-17	2008-05-22	Raqualia Pharma Inc.	Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja)	2007-03-08	2008-09-25	Kotobuki Seiyaku Kk	ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en)	2007-03-21	2008-09-25	Raqualia Pharma Inc.	Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124518A1 (en)	2007-04-03	2008-10-16	Janssen Pharmaceutica N.V.	Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
WO2008124524A2 (en)	2007-04-03	2008-10-16	Janssen Pharmaceutica N.V.	Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2009000413A1 (en)	2007-06-26	2008-12-31	Sanofi-Aventis	A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
RU2379043C2 (ru)	2007-08-02	2010-01-20	Закрытое акционерное общество "Биологические исследования и системы"	Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
US20110105515A1 (en)	2007-08-07	2011-05-05	President And Fellows Of Harvard College	Targeting the oncoprotein nucleophosmin
AR073578A1 (es)	2008-09-15	2010-11-17	Priaxon Ag	Pirrolidin-2-onas
WO2010036316A1 (en)	2008-09-24	2010-04-01	Yangbo Feng	Urea and carbamate compounds and analogs as kinase inhibitors
JPWO2010113458A1 (ja)	2009-03-31	2012-10-04	ゼリア新薬工業株式会社	１，５−ベンゾジアゼピン誘導体の製造法
EP2452680B1 (en)	2009-07-09	2019-12-18	RaQualia Pharma Inc.	Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
EP2480549B1 (en)	2009-09-24	2015-04-08	Fundación Centro Nacional De Investigaciones Oncológicas Carlos III	Fused imidazo[3,2-d]pyrazines as PI3 kinase inhibitors
HRP20160967T1 (hr)	2009-10-06	2016-10-07	Millennium Pharmaceuticals, Inc.	Heterociklički spojevi korisni kao pdk1 inhibitori
US9181414B2 (en)	2009-11-13	2015-11-10	Plastipak Packaging, Inc.	Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en)	2009-11-18	2011-05-26	Steady Sleep Rx Co., Inc.	Sustained release cannabinoid medicaments
CA2812043A1 (en)	2010-04-23	2011-10-27	Kineta, Inc.	Pyrimidinedione anti-viral compounds
WO2012021837A2 (en)	2010-08-12	2012-02-16	Senomyx, Inc.	Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
US20120231083A1 (en)	2010-11-18	2012-09-13	The Board Of Trustees Of The University Of Illinois	Sustained release cannabinoid medicaments
WO2012068516A2 (en)	2010-11-18	2012-05-24	Pier Pharmaceuticals	Low dose cannabinoid medicaments
EP2651405A2 (en)	2010-12-14	2013-10-23	Electrophoretics Limited	Casein kinase 1 (ck1 ) inhibitors
WO2013017480A1 (en)	2011-07-29	2013-02-07	Cellzome Limited	Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en)	2011-07-29	2013-02-07	Cellzome Limited	Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
ES2736603T3 (es)	2011-11-07	2020-01-03	Massachusetts Inst Technology	Complejos de wolframio oxo alquilideno para la metátesis de olefinas selectiva de Z
US10080805B2 (en)	2012-02-24	2018-09-25	Purdue Research Foundation	Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
TWI610916B (zh)	2012-08-03	2018-01-11	廣東東陽光藥業有限公司	作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en)	2012-08-06	2015-02-10	Amgen Inc.	Chroman derivatives as TRPM8 inhibitors

2014
- 2014-11-21 DK DK14815149.1T patent/DK3071206T3/da active
- 2014-11-21 AU AU2014352875A patent/AU2014352875B2/en active Active
- 2014-11-21 CA CA2929858A patent/CA2929858C/en active Active
- 2014-11-21 ES ES14815149T patent/ES2870538T3/es active Active
- 2014-11-21 KR KR1020167015759A patent/KR102254957B1/ko active Active
- 2014-11-21 CN CN201480073822.0A patent/CN106163527A/zh active Pending
- 2014-11-21 WO PCT/US2014/066832 patent/WO2015077572A1/en not_active Ceased
- 2014-11-21 MX MX2016006657A patent/MX2016006657A/es unknown
- 2014-11-21 US US14/550,233 patent/US10709714B2/en active Active
- 2014-11-21 EP EP14815149.1A patent/EP3071206B1/en active Active
- 2014-11-21 BR BR112016011727A patent/BR112016011727A2/pt not_active Application Discontinuation
- 2014-11-21 JP JP2016533607A patent/JP6502939B2/ja active Active
- 2014-11-21 RU RU2016124538A patent/RU2693484C1/ru active
- 2014-11-21 PL PL14815149T patent/PL3071206T3/pl unknown

Also Published As

Publication number	Publication date
BR112016011727A2 (pt)	2017-08-08
JP2016538295A (ja)	2016-12-08
EP3071206A1 (en)	2016-09-28
RU2016124538A (ru)	2017-12-27
CA2929858A1 (en)	2015-05-28
KR102254957B1 (ko)	2021-05-25
WO2015077572A1 (en)	2015-05-28
EP3071206B1 (en)	2021-02-17
US20150148339A1 (en)	2015-05-28
RU2693484C1 (ru)	2019-07-03
DK3071206T3 (da)	2021-05-25
AU2014352875A8 (en)	2016-06-30
US10709714B2 (en)	2020-07-14
PL3071206T3 (pl)	2022-01-17
CA2929858C (en)	2022-03-29
AU2014352875A1 (en)	2016-05-26
ES2870538T3 (es)	2021-10-27
KR20160088891A (ko)	2016-07-26
CN106163527A (zh)	2016-11-23
AU2014352875B2 (en)	2019-10-24
MX2016006657A (es)	2016-10-12

Legal Events

Date	Code	Title	Description
2016-10-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161007
2017-11-16	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116
2017-11-16	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171116
2018-07-31	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731
2018-10-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181030
2019-02-12	TRDD	Decision of grant or rejection written
2019-02-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190219
2019-03-28	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190322
2019-03-29	R150	Certificate of patent or registration of utility model	Ref document number: 6502939 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2022-03-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-03-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-03-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-03-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-01-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
Castañeda et al.	2012	Subchondral bone as a key target for osteoarthritis treatment
Tabatabaei-Malazy et al.	2017	New horizons in treatment of osteoporosis
Lupsa et al.	2015	Bone health and osteoporosis
Folli et al.	2012	Bariatric surgery and bone disease: from clinical perspective to molecular insights
Thomas	2006	Intermittent parathyroid hormone therapy to increase bone formation
Israeli et al.	2008	Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy
Figliomeni et al.	2018	One year in review 2018: progress in osteoporosis treatment
Argilés et al.	2008	Novel approaches to the treatment of cachexia
JP6502939B2 (ja)	2019-04-17	骨粗鬆症の処置及び予防のためのガストリン拮抗薬
ESHRE Capri Workshop Group	2010	Bone fractures after menopause
Watanabe et al.	2016	Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy
Zhou et al.	2018	Electroacupuncture ameliorates subchondral bone deterioration and inhibits cartilage degeneration in ovariectomised rats
Abo-Elenin et al.	2024	An overview of osteoporosis and possible treatment approaches
Gowen et al.	2000	Emerging therapies for osteoporosis
Mohanty et al.	2025	Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review: S. Mohanty et al.
Igarashi et al.	2023	Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats
Stathopoulos et al.	2014	A review on osteoporosis in men
Appelman-Dijkstra et al.	2013	Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches
Vashghani Farahani et al.	2017	The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model
HK1230487A1 (en)	2017-12-08	Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Fasipe et al.	2021	Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review
Bao et al.	2020	Lithium chloride enhances osteoblast differentiation and resists senile osteoporosis
Abo-Rayah et al.	2023	Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats
Zhu	2022	Targeting TGFβ1 Signaling: A Sustained-release, Monthly Intra-articular Injection Intervention for Early Osteoarthritis
Crosignani	2010	Bone fractures after menopause.